Skip to content

Reducing ribavirin and adding EPO are both good anaemia management strategies for people taking boceprevir

Eric Lawitz from Alamo Medical Research, Texas © Liz Highleyman / hivandhepatitis.com

Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C

Kris Kowdley, Liver Center of Excellence at Virginia Mason Medical Center, Seattle © Liz Highleyman / hivandhepatitis.com

High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype

Final study results show telaprevir is safe and effective for HIV/HCV co-infected people

Mark Sulkowski from Johns Hopkins University School of Medicine.  © Liz Highleyman / hivandhepatitis.com

New hepatitis C drugs danoprevir and mericitabine are safe and effective for prior non-responders and people with cirrhosis

New cohort shows the impact of hepatitis B and hepatitis C on the 'baby boom' generation

Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis

Antiviral treatment reduces risk of liver cancer in people with hepatitis C-related cirrhosis and fibrosis

European guidelines on management of mental health for people with hepatitis C published